Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Byrd

Showing results (801-810 of 903) with videos related to

Pageof 91
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 15, 2009
Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk diseaseThomas S Lin, Amy S Ruppert, Amy J Johnson, et al.
Leukemia|November 14, 2022
VIP152 is a selective CDK9 inhibitor with pre-clinical in vitro and in vivo efficacy in chronic lymphocytic leukemiaSteven Sher, Ethan Whipp, Janek Walker, et al.
Blood|March 8, 2019
Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumabJohn C Byrd, Peter Hillmen, Susan O'Brien, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2011
Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoproteinCraig C Hofmeister, Xiaoxia Yang, Flavia Pichiorri, et al.
Blood|October 24, 2002
Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemiaGuido Marcucci, John C Byrd, Guowei Dai, et al.
Leukemia|November 27, 2012
Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemiaA Mims, A R Walker, X Huang, et al.
Blood|April 8, 2026
Genotype-immunophenotype relationships in NPM1-mutated AML clonal evolution uncovered by single-cell multiomic analysisMorgan Drucker, Darren Lee, Michael S Bowman, et al.
Blood|June 28, 2015
Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 studySamantha M Jaglowski, Jeffrey A Jones, Veena Nagar, et al.
Cancer Discovery|August 11, 2018
The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter TransformationSean D Reiff, Rose Mantel, Lisa L Smith, et al.
Nature Genetics|January 19, 2016
DNA methylation dynamics during B cell maturation underlie a continuum of disease phenotypes in chronic lymphocytic leukemiaChristopher C Oakes, Marc Seifert, Yassen Assenov, et al.
Pageof 91

Showing results (801-810 of 903) with videos related to

Sort By:
Pageof 91
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 15, 2009
Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk diseaseThomas S Lin, Amy S Ruppert, Amy J Johnson, et al.
Leukemia|November 14, 2022
VIP152 is a selective CDK9 inhibitor with pre-clinical in vitro and in vivo efficacy in chronic lymphocytic leukemiaSteven Sher, Ethan Whipp, Janek Walker, et al.
Blood|March 8, 2019
Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumabJohn C Byrd, Peter Hillmen, Susan O'Brien, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2011
Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoproteinCraig C Hofmeister, Xiaoxia Yang, Flavia Pichiorri, et al.
Blood|October 24, 2002
Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemiaGuido Marcucci, John C Byrd, Guowei Dai, et al.
Leukemia|November 27, 2012
Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemiaA Mims, A R Walker, X Huang, et al.
Blood|April 8, 2026
Genotype-immunophenotype relationships in NPM1-mutated AML clonal evolution uncovered by single-cell multiomic analysisMorgan Drucker, Darren Lee, Michael S Bowman, et al.
Blood|June 28, 2015
Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 studySamantha M Jaglowski, Jeffrey A Jones, Veena Nagar, et al.
Cancer Discovery|August 11, 2018
The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter TransformationSean D Reiff, Rose Mantel, Lisa L Smith, et al.
Nature Genetics|January 19, 2016
DNA methylation dynamics during B cell maturation underlie a continuum of disease phenotypes in chronic lymphocytic leukemiaChristopher C Oakes, Marc Seifert, Yassen Assenov, et al.
Pageof 91